MabVax Raises $3M, Completes Merger With Telik

San Diego-based MabVax Therpauetics, a privately held firm which is developing vaccine and antibody therapies for treating cancer, said it has raised $3M in a financing round, and also completed a merger with oncology drug developer Telik. MabVax said the investment came from accredited investors, and was managed by H.C. Wainwright & Co., LLC, Palladium Capital Advisors LLC and Dawson James Securities. MabVax said that it has become a wholly owned subsidiary of Telik in an all-stock transaction.